# Myositis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/myositis

> 2 upcoming FDA catalysts in myositis: PF-06823859 (PFE) on Jul to Oct 2030 (topline data readout); PF-06823859 (PFE) on July 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 4, 2025 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myositis | completed | "NCT05379634 (A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05379634)) |
| Jul to Oct 2030 | [PF-06823859 topline data readout](https://sec-api.dev/pdufa/pf-06823859) | PFE | Myositis | scheduled | "NCT05895786 (A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05895786)) |
| July 2030 | [PF-06823859 primary completion](https://sec-api.dev/pdufa/pf-06823859) | PFE | Myositis | scheduled | "NCT05895786 (A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05895786)) |

## Drugs

- [IMAAVY (nipocalimab)](https://sec-api.dev/pdufa/nipocalimab) (JNJ)
- [PF-06823859](https://sec-api.dev/pdufa/pf-06823859) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/myositis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Myositis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/myositis

```bibtex
@misc{secapidev_indications_myositis_20261116,
  title        = {Myositis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/myositis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_myositis_20261116","title":"Myositis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/myositis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
